Pseudomonas aeruginosa

Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

Retrieved on: 
Monday, December 20, 2021
COVID, Solution, OTC, CLAS, Company, Death, Office of Inspector General, U.S. Department of Health and Human Services, Septic shock, Biomedical Advanced Research and Development Authority, Bamlanivimab, Adult, Brain, Times New Roman, Sepsis, SAN, Proning, COVID-19, Female, USD, Transfusion-related acute lung injury, PHASE 2, Dexamethasone, Liver, CEO, Pseudomonas aeruginosa, Patient, Mortality, Tissue, Leadership, Infection, U.S. Department of Defense Strategy for Operating in Cyberspace, Human services, University, GLOBE, Scientific Reports, High-dependency unit, Sheep, TSX, Trial of the century, Heart, Pharmaceutical industry

R-107 was evaluated in a controlled large animal (sheep) model of sepsis, with significantly positive results.

Key Points: 
  • R-107 was evaluated in a controlled large animal (sheep) model of sepsis, with significantly positive results.
  • These results unequivocally demonstrated that R-107 reduced mortality, and provide important support for the Companys development of R-107 for COVID-19 related sepsis.
  • Claritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.
  • Claritas leverages its expertise to find solutions that will improve health outcomes and dramatically improve people's lives.

Livia Global Announces Voluntary Recall of Two Lots of its LiviaOne Liquid Probiotics because of the Potential for Contamination with Pseudomonas Aeruginosa

Retrieved on: 
Wednesday, December 1, 2021
Medical Supplies, Health, Other Health, Other Science, General Health, Science, Safety, Environment, PST, See, Immunodeficiency, Health, Global, Lot, Pseudomonas aeruginosa, Infection, Probiotic, Dietary supplement, Online shopping

Livia Global, Inc. a health and wellness company that offers LiviaOne Liquid Probiotics & BioLifePet Liquid Probiotics, today announced that it is voluntarily recalling two lots of its liquid probiotics due to the possibility of contamination by Pseudomonas aeruginosa.

Key Points: 
  • Livia Global, Inc. a health and wellness company that offers LiviaOne Liquid Probiotics & BioLifePet Liquid Probiotics, today announced that it is voluntarily recalling two lots of its liquid probiotics due to the possibility of contamination by Pseudomonas aeruginosa.
  • Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals.
  • (See below) No other lots or ship dates or any other LiviaOne products are affected by this recall.
  • Impacted consumers may contact Livia Global Customer Care to request a full refund (please have order # available), see contact information provided below.

OhmniLabs Unveils The World's Lightest, Most Efficient Autonomous UV-C Cleaning Robot

Retrieved on: 
Tuesday, November 16, 2021
Health Data Insight, Transport, Full, Maintenance, Disinfectant, Pseudomonas aeruginosa, HEPA, Student, SAN, Education, Carnegie Mellon University, Hospital, Infection, 3D, Severe acute respiratory syndrome coronavirus 2, Escherichia coli, Use, Research, Running, Silicon, Bacteria, UV, Environment, Stanford University, HVAC, VRE, School, MRSA, Efficiency, Risk, Premium, Sewage, 3D printing

SAN JOSE,Calif., Nov. 16, 2021 /PRNewswire/ --OhmniLabs, an award-winning robotics company, today introduced OhmniClean, a fully autonomous robot that disinfects utilizing the power of UV-C light.

Key Points: 
  • SAN JOSE,Calif., Nov. 16, 2021 /PRNewswire/ --OhmniLabs, an award-winning robotics company, today introduced OhmniClean, a fully autonomous robot that disinfects utilizing the power of UV-C light.
  • Weighing just 58 pounds, OhmniClean is the world's lightest and most user-friendly high-powered UV-C Disinfection robot available today.
  • A fully autonomous UV-C robot has many advantages over human, manual-controlled cleaning systems.
  • OhmniLabs robots are used daily by businesses, medical professionals, schools, and major sports teams around the world.

ContraFect’s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis

Retrieved on: 
Tuesday, November 9, 2021
People, Antimicrobial, Pseudomonas aeruginosa, Endocarditis, Clinical trial, Security (finance), SOC, Family, MDR, Acinetobacter baumannii, Infection, Pneumonia, Cough, Peptide, Mortality, Person, Trial of the century, Standard of care, Forward-looking statement, GN, Conference, U.S. Securities and Exchange Commission, GLOBE, Fever, MRSA, Subclinical infection, Poster, Patient, Biofilm, FDA, Enterobacter, AM1, BSI, Campaign, Breakthrough therapy, Inflammation, Achromobacter, DLA, Virus, Fungus, Cystic fibrosis, Mucus, Osteomyelitis, Maintenance, Rockefeller University, Stenotrophomonas maltophilia, Bacteria, Lysin, Bloodstream infections, Nasdaq, Death, Pharmaceutical industry, Vaccine

According to the Cystic Fibrosis (CF) Foundation, infections are a problem for people with cystic fibrosis because they can cause fever, difficulty breathing, coughing, and excessive inflammation. A cycle of recurring infections and inflammation gradually destroys lung tissue. People with CF are susceptible to infections from bacteria, viruses, and fungi because abnormally thick, sticky mucus traps these germs in the airways. They also are prone to infections because their mucus and airway liquid does not have the same infection-fighting properties as normal mucus. This abnormal mucus provides an ideal environment for bacteria to form protective layers -- known as biofilms -- that make them more difficult to kill. For more information visit: https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/

Key Points: 
  • These data were recently presented at the North American Cystic Fibrosis Conference (NACFC) which was held virtually from November 2-5, 2021.
  • These direct lytic agents show in vitro activity against the most prevalent Gram-negative pathogens, including multi-drug resistant (MDR) strains commonly associated with pulmonary infections in patients with cystic fibrosis.
  • Currently, few treatment options exist to address these infections, and persons with cystic fibrosis are even more vulnerable.
  • According to the Cystic Fibrosis (CF) Foundation, infections are a problem for people with cystic fibrosis because they can cause fever, difficulty breathing, coughing, and excessiveinflammation.

Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress

Retrieved on: 
Thursday, November 4, 2021
MSD, Medication, DEL, Time, Armata, Drug development, Merck, NYSE, Staphylococcus aureus, GMP, Phage therapy, Congress, Pseudomonas aeruginosa, Infection, Drug, Urinary tract infection, Therapy, Pharmaceutical industry

In its seventh year, the Congress will attract more than 400 attendees from around the world and features more than 150 speakers.

Key Points: 
  • In its seventh year, the Congress will attract more than 400 attendees from around the world and features more than 150 speakers.
  • It is the world's largest and most commercially focused gathering of antimicrobial resistance stakeholders globally.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing its bacteriophage-based technology with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 4, 2021
Safety, Acinetobacter, Entasis, Gram, Failure, Test, Ceftriaxone, Infection, Patient, Marketing, Insurance, Pseudomonas aeruginosa, Private Securities Litigation Reform Act, Nephrotoxicity, U.S. Securities and Exchange Commission, Data, National Rural Development Partnership, Leadership, Colistin, Forward-looking statement, Nature, Company, Clinical trial, Webcast, Cooperative, Diversified Specialty Institute Holdings, Inc., NDA, News, Wellcome Trust, Gonorrhea, Nasdaq, Research, Mortality, Therapy, Flexion Therapeutics, GLOBE, Population, Pharmaceutical industry, Management, Vaccine

Mortality analyses in all pre-specified populations included in the topline results unequivocally favored SUL-DUR versus colistin.

Key Points: 
  • Mortality analyses in all pre-specified populations included in the topline results unequivocally favored SUL-DUR versus colistin.
  • Ms. Triolapreviously served as the Vice President, Marketing at Summit Therapeutics, and prior to that held leadership roles at Flexion Therapeutics, Chiasma, Cubist, and Biogen.
  • As of September 30, 2021, cash and cash equivalents were $44.1 million, compared to $53.2 million as of December 31, 2020.
  • The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update.

Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study

Retrieved on: 
Tuesday, November 2, 2021
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Safety, MHS, Duke University School of Medicine, MD, Sponsor, Diagnosis, Technology, University, Disease, Johns Hopkins School of Medicine, WRAIR, NIH, Duke University, Partnership, Person, Infection, Patient, Pseudomonas aeruginosa, FDA, Licensure, UC San Diego School of Medicine, Phage therapy, PST, Urinary tract infection, NIAID, Leadership, Risk, United States Department of Defense, National, University of California, San Diego Performance-Based Skills Assessment, Investigational New Drug, Cystic fibrosis, University of California, Pediatrics, Multimedia, Bacteria, APT, AMR, Program, National Institute, Therapy, Division, Health, Associate, Walter Reed Army Institute of Research, Bacteriophage, National Institute of Allergy and Infectious Diseases, Pharmaceutical industry

Under the agreement, APT will provide proprietary bacteriophages for use in the NIAID sponsored Phase 1b/2 clinical study.

Key Points: 
  • Under the agreement, APT will provide proprietary bacteriophages for use in the NIAID sponsored Phase 1b/2 clinical study.
  • We are honored and excited to partner with ARLG as they undertake efforts to address a significant unmet medical need related to cystic fibrosis.
  • Through FDA emergency use allowance, we have observed the potential of phage therapy as an effective treatment for cystic fibrosis patients with Pseudomonas aeruginosa lung infections.
  • Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.

Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility

Retrieved on: 
Tuesday, November 2, 2021
MSD, Medication, DEL, Drug development, Merck, AP, NYSE, Staphylococcus aureus, GMP, Phage therapy, SEC, Communication, Pseudomonas aeruginosa, Annual report, Forward-looking statement, Risk, Company, Clinical trial, Infection, COVID-19, Therapy, Bacteriophage, Pharmaceutical industry

"Armata's innovative phage therapy pipeline will be enhanced by our commitment to build out a new R&D facility that offers expanded GMP manufacturing capacity to support future pivotal studies and commercial launch," stated Dr. Brian Varnum, Chief Executive Officer of Armata.

Key Points: 
  • "Armata's innovative phage therapy pipeline will be enhanced by our commitment to build out a new R&D facility that offers expanded GMP manufacturing capacity to support future pivotal studies and commercial launch," stated Dr. Brian Varnum, Chief Executive Officer of Armata.
  • "In addition, we believe this new, state-of-the-art facility is essential for our novel product form given the scarcity of phage-specific manufacturing capacity.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing its bacteriophage-based technology with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Out of an Abundance of Caution MaryRuth's Announces Voluntary Recall of Two Lots of Its Liquid Probiotic for Infants Because of the Potential for Contamination With Pseudomonas aeruginosa

Retrieved on: 
Saturday, October 30, 2021
Food, Beverage, Consumer, Retail, Parenting, Baby, Maternity, Safety, Vitamin, Infection, UPC, Mineral, Blood, Family, Pseudomonas aeruginosa, Amazon (company), CEO, Environment, Multimedia, Health, Lot, Probiotic, Immunodeficiency, Dietary supplement, Online shopping

Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause infection in immunocompromised individuals or, rarely, in very young infants.

Key Points: 
  • Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause infection in immunocompromised individuals or, rarely, in very young infants.
  • P. aeruginosa infections in immunocompromised infants are generally limited to hospital settings.
  • View the full release here: https://www.businesswire.com/news/home/20211029005576/en/
    This recall only affects two lots of the product, Lot #100420218 and Lot #100520218, UPC barcode number 856645008587.
  • MaryRuths offers a large portfolio of liquid, gummy, and chewable products spanning multiple categories, including multivitamins, probiotics, herbal supplements, and more.

Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021

Retrieved on: 
Thursday, October 28, 2021
Entasis, Infection, NASDAQ, Conference, Pseudomonas aeruginosa, Webcast, Wright Investors' Service Holdings, Inc., Therapy, GLOBE, Enterobacteriaceae, Pharmaceutical industry

WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021.

Key Points: 
  • WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021.
  • The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update.
  • A replay of the call will be available from the Entasis website at www.entasistx.com following the call.
  • Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.